These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 15661883)

  • 1. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
    Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
    Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA.
    Koido S; Kashiwaba M; Chen D; Gendler S; Kufe D; Gong J
    J Immunol; 2000 Nov; 165(10):5713-9. PubMed ID: 11067929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P; Serre K; Baillet M; Leserman L
    J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
    Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
    J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
    Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
    J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
    Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
    Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
    Stober D; Jomantaite I; Schirmbeck R; Reimann J
    J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
    Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
    Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
    Shibagaki N; Udey MC
    J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
    Koido S; Enomoto Y; Apostolopoulos V; Gong J
    Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments.
    Kang TH; Lee JH; Bae HC; Noh KH; Kim JH; Song CK; Shin BC; Hung CF; Wu TC; Park JS; Kim TW
    Immunol Lett; 2006 Aug; 106(2):126-34. PubMed ID: 16844231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells.
    Koido S; Hara E; Homma S; Torii A; Mitsunaga M; Yanagisawa S; Toyama Y; Kawahara H; Watanabe M; Yoshida S; Kobayashi S; Yanaga K; Fujise K; Tajiri H
    J Immunol; 2007 Jan; 178(1):613-22. PubMed ID: 17182602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.
    Gerner MY; Mescher MF
    J Immunol; 2009 Mar; 182(5):2726-37. PubMed ID: 19234167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo.
    Kleindienst P; Brocker T
    J Immunol; 2003 Mar; 170(6):2817-23. PubMed ID: 12626531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.